Posts Tagged ‘vaccines’

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

Courtesy of David Kirby at The Huffington Post 

If it seems like most of the people you know with autism are 22 or younger, that’s because most people diagnosed with autism were born after 1987. A recent US EPA study has found a distinct "changepoint" year – or spike – in autism in California and elsewhere and concludes that it would be "prudent to assume that at least some portion of this increase is real and results from environmental factors."

"In the Danish, California, and worldwide data sets, we found that an increase in autism disorder cumulative incidence began about (the birth cohort years) 1988-1989," wrote the authors Michael E. Mc Donald and John F. Paul, of the EPA’s National Health and Environmental Effects Research Laboratory.

"Although the debate about the nature of increasing autism continues," they added, "the potential for this increase to be real and involve exogenous (external) environmental stressors exists."

But it was the distinct timing in the increase of autism – the birth of an epidemic, as many believe – that was most notable, and which "may help in screening for potential candidate environmental stressors."

"The calculated year was determined to be significant," the EPA scientists said. The rate of increase before 1988 "was significantly different" than the rate after that year (the "postchangepoint," in epidemiology parlance). In California, the rate spiked from 5.7-per-10,000 before the changepoint, to 20.8-per 10,000 in its wake, and the worldwide dataset showed a similar jump (from 6.0 to 24.2). In Denmark, the rise was even more dramatic, though total incidence was only a fraction of that in the US: from 0.6 to 6.6.

(A study in Japan from 1988-1996 showed continuously increasing autism rates, but no calculable changepoint year – please see the full report for a discussion on study limitations).

So why would rates more than triple in California kids born before and after 1988? Is…
continue reading


Tags: , , , , , , , , , ,




Double-Edged Sword: Swine Flu and Vaccines

By guest author Terry Doherty and Ilene, your editor

Terry Doherty is the Research Program Coordinator in the Depts of Biomedical Sciences and Academic Affairs at Cedar Sinai in Los Angeles, California.

Double-Edged Sword: Swine Flu and Vaccines

There’s plenty that is unknown about the swine flu and the swine flu vaccine.  If searches on the internet are any indication, deciding whether or not to be vaccinated may be a tough, emotionally charged decision for many people.  So how – without having the background to write a swine flu grant proposal, conduct the research, and get the thing published in the New England Journal of Medicine – do we decide whether or not to get a swine flu shot?  

One way is to attempt to evaluate and weigh the risks of the vaccine against the risks of the flu.  That is how I approach the subject, but it’s easier said than done.  As is often the case with medical interventions, the risks are not fully known. And even if we could carefully assess the risks, our underlying assumptions may be wrong.  Percent risks are averages collected by studying large populations.  We may not be one of the statistical average.  Then there are the gaps in the available data, and own biases and belief systems.  Our view of the world affects our analysis and often we are not even aware of how large of an effect those biases may play.   

In Vaccine War: Autism, Flu and Science, TIME, Maia Szalavitz discusses how emotion and biases play a large part in our risk-benefit assessments:

Just in time for the national roll-out of the new H1N1 flu vaccine, Wired Magazine and the Atlantic have weighed in on the ongoing vaccine war: Wired has a profile of Paul Offit, a vaccine researcher and pediatrician who has consistently spoken out in favor of vaccination and pointed to the lack of evidence linking vaccines and autism; the Atlantic checks in with a piece questioning the science suggesting that flu vaccines and antiviral drugs prevent people from dying.

Both articles have elicited heated debate all over the Web: Amy Wallace, who wrote Wired’s piece, excerpted below, has received vitriolic criticism and attacks from vaccine opponents, setting records for page views…

This debate over vaccination doesn’t seem likely to end any time soon. For critics, vaccines…
continue reading


Tags: , , , , , , , , , , , ,




In Germany, A Better H1N1 Vaccine For Politicians?

For additional reading on the swine flu vaccine situation in Germany, see the article at the end translated by my friend Bob, in red.  Thank you Bob. - Ilene

In Germany, A Better H1N1 Vaccine For Politicians?

vaccinesBy Tristana Moore / Berlin, Courtesy of TIME

Critics are calling it a two-tier health system — one for the politically well-connected, another for the hoi polloi. As Germany launched its mass vaccination program against the H1N1 flu virus on Monday, the government found itself fending off accusations of favoritism by offering one vaccine believed to have fewer side effects to civil servants, politicians and soldiers, and another potentially riskier vaccine to everyone else. The government had hoped that Germans would rush to health clinics to receive vaccinations against the rapidly spreading disease, but the rising anger over the different doses may now cause many people to shy away.

Amid growing fears over a possible global flu pandemic, the German government prepared for its mass vaccination campaign earlier this year by ordering 50 million doses of the Pandemrix vaccine, which would be enough for a double dose for 25 million people, around a third of the population. The vaccine, manufactured by GlaxoSmithKline, contains an immune-enhancing chemical compound, known as an adjuvant, whose side effects are not yet entirely known. Then, after a report was leaked to the German media last week, the Interior Ministry confirmed that it had ordered a different vaccine, Celvapan, for government officials and the military. Celvapan, which is made by the U.S. pharmaceutical giant Baxter, does not contain an adjuvant and is believed to have fewer side effects than Pandemrix.

Anger at the news was widespread in Germany. "If mass vaccination is considered to be necessary, then everyone should be treated the same way," says Birgitt Bender, the health spokeswoman for the Green Party. Ulrike Mascher, head of the VdK social welfare association, said giving government officials a different vaccine from the rest of the population sent the "wrong signal" and gave many people "the impression that they are second-class patients." A story on the front page of the mass-circulation Bild newspaper accused the government of giving "second-class medicine" to regular Germans.

Doctors and medical experts are divided over the safety of Pandemrix. While some say it’s the best vaccine available, others have serious misgivings about it. "The Pandemrix vaccine can’t be recommended…
continue reading


Tags: , , , , ,




New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Weekend off-topic reading.  I found this fascinating. - Ilene  

New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Courtesy of David Kirby writing at the Huffington Post

"The science is largely complete. Ten epidemiological studies have shown MMR vaccine doesn’t cause autism; six have shown thimerosal doesn’t cause autism."-- Dr. Paul Offit, "Autism’s False Prophets"

"16 studies have shown no causal association between vaccines and autism, and these studies carry weight in the scientific industry."-- Dr. Nancy Snyderman, NBC Today Show Medical Editor

Conventional wisdom holds that the autism-vaccine question has been "asked and answered," and that at least 16 large, well-constructed epidemiological studies have thoroughly addressed and debunked any hypothesis that childhood vaccination is in any way associated with an increased risk for autism spectrum disorders.

But there are several critical flaws in such an oversimplified generalization, and they are rarely given close examination by public health experts or members of the media.

To begin with, it is unscientific and perilously misleading for anyone to assert that "vaccines and autism" have been studied and that no link has been found. That’s because the 16 or so studies constantly cited by critics of the hypothesis have examined just one vaccine and one vaccine ingredient.

And, the population studies themselves have had critical design flaws and limitations.

The current US childhood immunization schedule calls for 28 injections with 11 different vaccines against 15 different diseases by two years of age. Of those 11 vaccines, only the Measles-Mumps-Rubella (MMR) shot has been studied in association with autism, (although a CDC study of an MMR-plus-chickenpox vaccine did show that the risk for febrile seizures in infants was doubled.) Meanwhile, those 11 vaccines contain scores of ingredients, only one of which, thimerosal, has ever been tested in association with autism.

It is illogical to exonerate all vaccines, all vaccine ingredients, and the total US vaccine program as a whole, based solely on a handful of epidemiological studies of just one vaccine and one vaccine ingredient. It is akin to claiming that every form of animal protein is beneficial to people, when all you have studied is fish.

Now, a new study has shown that giving Hepatitis B vaccine to newborn baby boys may triple the risk of developing an autism spectrum disorder.

An abstract of the study was published in the September, 2009…
continue reading


Tags: , , , , , , ,




Swine Flu Vaccine: Watching For Side Effects

The decision regarding whether or not to get vaccinated for swine flu, or have your kids vaccinated, may be easy for some, but is not for others. It depends on how you perceive and value the risks. As is often the case with medical interventions, the risks are not fully known or understood. Even if you’re lucky enough to believe you’ve obtained valid risk percentages to compare, you cannot truly know whether your assumptions accurately reflect reality. And your numbers certainly don’t factor in the unknown.

So as the swine flu vaccine program gets underway, several government-sponsored projects will attempt to determine how safe the vaccine really is. We have a rather unique opportunity to learn a lot more while serving as subjects in this grand experiment.

Go ahead, leave comments and share your thoughts… – Ilene

Swine Flu Vaccine: Watching For Side Effects

(WASHINGTON) — More than 3,000 people a day have a heart attack. If you’re one of them the day after your swine flu shot, will you worry the vaccine was to blame and not the more likely culprit, all those burgers and fries?

The government is starting an unprecedented system to track possible side effects as mass flu vaccinations begin next month. The idea is to detect any rare but real problems quickly, and explain the inevitable coincidences that are sure to cause some false alarms.

"Every day, bad things happen to people. When you vaccinate a lot of people in a short period of time, some of those things are going to happen to some people by chance alone," said Dr. Daniel Salmon, a vaccine safety specialist at the Department of Health and Human Services.

Health authorities hope to vaccinate well over half the population in just a few months against swine flu, which doctors call the 2009 H1N1 strain. That would be a feat. No more than 100 million Americans usually get vaccinated against regular winter flu, and never in such a short period.

How many will race for the vaccine depends partly on confidence in its safety. The last mass inoculations against a different swine flu, in 1976, were marred by reports of a rare paralyzing condition, Guillain-Barre syndrome.

"The recurring question is, ‘How…
continue reading


Tags: , , , , , , ,




 
 
 

Phil's Favorites

WeWork's Unraveling Is Another Indictment of Wall Street's Universal Bank Model

Courtesy of Pam Martens

Adam Neumann, Founder of WeWork

WeWork is just one more in a long series of Wall Street scandals that prove that the universal banking model is little more than a thinly-disguised wealth transfer system from the pockets of average Americans to the 1 percent.

Just two months ago WeWork’s two lead Wall Street underwriters, JPMorgan Chase and Goldman Sachs, were planning to offer WeWork’s shares to the public investor at a valuation in excess of $47 billion. Now we are learning that the company may run out of money next month and has an actual valuation of $8 billion or less.

WeWork’s founder, Adam Neumann, w...



more from Ilene

Zero Hedge

Under Armour CEO Plank Steps Down One Year After #MeToo Crisis 

Courtesy of ZeroHedge View original post here.

Under Armor's stock is up several percent in pre-market trading after Kevin Plank, founder/CEO of the apparel company, is stepping down after more than two decades. Chief Operating Officer Patrik Frisk will replace Plank, effective Jan. 01, reported CNBC

Plank will take a more passive role in daily operations in 2020, will transition to executive chairman and brand chief.

"Patrik is the right person to serve as Und...



more from Tyler

Insider Scoop

Roku To Purchase Dataxu For $150M In Cash And Roku Shares

Courtesy of Benzinga

Roku, Inc. (NASDAQ: ROKU) has entered into an agreement to acquire Boston-based Dataxu, a demand-side platform, for $150 million in cash and Roku shares.

Dataxu provides marketers with an automated bidding and self-serve software to manage ad campaigns progr...



http://www.insidercow.com/ more from Insider

The Technical Traders

Indexes Struggle and TRAN suggests a possible top

Courtesy of Technical Traders

Nearing the end of October, traders are usually a bit more cautious about the markets than at other times of the year. History has proven that October can be a month full of surprises.  It appears in 2019 is no different. Right now, the markets are still range bound and appear to be waiting for some news or other information to push the markets outside of the defined range.

We still have at least one more trading week to go in October, yet the US markets just don’t want to move away from this 25,000 to 27,000 range for the Dow Industrials. In fact, since early 2019, we have traded within a fairly moderate price range of about 3200 points on the YM – a rotation...



more from Tech. Traders

Kimble Charting Solutions

Apple Bullish Breakout Suggesting Tech Follows In Its Path?

Courtesy of Chris Kimble

Is Apple sending a bullish message to the overall Tech market? Sure could be

Apple (AAPL) is working on a breakout above last year’s highs at (1), after creating a series of higher lows over the past year.

Tech ETF QQQ has been a similar-looking pattern to Apple over the past few months, as it is near old highs while creating higher lows.

Is Apple’s upside breakout suggesting that QQQ will follow in its footsteps and breakout?

Str...



more from Kimble C.S.

Digital Currencies

Five hurdles blockchain faces to revolutionise banking

 

Five hurdles blockchain faces to revolutionise banking

Shutterstock

Courtesy of Markos Zachariadis, Warwick Business School, University of Warwick

Blockchain is touted as the next step in the digital revolution, a technology that will change every industry from music to wast...



more from Bitcoin

Chart School

Gold Stocks Review

Courtesy of Read the Ticker

Gold stocks are swinging back forth between the range, and a break out swing higher is due. Gold stocks are holding a near perfect Wyckoff accumulation pattern. All should get ready to play this sector. Yet we must recognize that gold stocks are a one of the most crazy rides at the stock market fair, so play very carefully.

More from RTT Tv







GDX PnF chart from within the video

Click for popup. Clear your browser cache if image is not showing.




Important channels around the HUI.
...

more from Chart School

Lee's Free Thinking

Look Out Bears! Fed New QE Now Up to $165 Billion

Courtesy of Lee Adler

I have been warning for months that the Fed would need new QE to counter the impact of massive waves of Treasury supply. I thought that that would come later, rather than sooner. Sorry folks, wrong about that. The NY Fed announced another round of new TOMO (Temporary Open Market Operations) today.

In addition to the $75 billion in overnight repos that the Fed issued and has been rolling over since Tuesday, next week the Fed will issue another $90 billion. They’ll come in the form of three $30 billion, 14 day repos to be offered next week.

That brings the new Fed QE to a total of $165 billion. Even in the worst days of the financial crisis, I can’t remember the Fed ballooning its balance sheet by $165 bi...



more from Lee

Biotech

The Big Pharma Takeover of Medical Cannabis

Reminder: We are available to chat with Members, comments are found below each post.

 

The Big Pharma Takeover of Medical Cannabis

Courtesy of  , Visual Capitalist

The Big Pharma Takeover of Medical Cannabis

As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless co...



more from Biotech

Mapping The Market

How IPOs Are Priced

Via Jean Luc 

Funny but probably true:

...

more from M.T.M.

Members' Corner

Despacito - How to Make Money the Old-Fashioned Way - SLOWLY!

Are you ready to retire?  

For most people, the purpose of investing is to build up enough wealth to allow you to retire.  In general, that's usually enough money to reliably generate a year's worth of your average income, each year into your retirement so that that, plus you Social Security, should be enough to pay your bills without having to draw down on your principle.

Unfortunately, as the last decade has shown us, we can't count on bonds to pay us more than 3% and the average return from the stock market over the past 20 years has been erratic - to say the least - with 4 negative years (2000, 2001, 2002 and 2008) and 14 positives, though mostly in the 10% range on the positives.  A string of losses like we had from 2000-02 could easily wipe out a decades worth of gains.

Still, the stock market has been better over the last 10 (7%) an...



more from Our Members

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>